Policy & Medicine - Legal, Regulatory, and Compliance Issues

In a city where crime rates are sky-high and illegal drugs are easily picked up on the street, on November 16, 2016, the City of…

On January 12, 2017, the U.S. Department of Justice (DOJ) announced publicly that Zimmer Biomet Holdings, Inc. (Zimmer…

Many in political (and non-political) circles have blamed a lack of pricing transparency for increasing healthcare costs. However,…

In a last-minute attempt to put a permanent mark on the life sciences (and specifically, the medical device) industry, the…

As many of our readers know all too well, pharmaceutical companies are not permitted to discuss off-label, legal, alternative uses…

Last Friday, several of our readers emailed us last week to let us know that they were having difficulty with logging in and…

We have written for years about the transition in health care from volume-based to value-based payment models. But the process has…

The 4th Due Diligence Summit for Life Sciences, taking place on May 18 and 19 of this year in Boston, Massachusetts at the Hyatt…

Part of President Obama’s landmark health care bill, the Affordable Care Act, imposed a federal tax on medical devices. That tax…

In late-February, we reported that CMS had recently finalized new Innovation Center models. However, now, in an interim rule, CMS…